Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $57.1M | $860K | $1.81M | $705K | $0.00 | $0.00 | — |
| Revenue growth | — | -98.5% | 110.3% | -61.0% | -100.0% | — | — |
| Operating income | $5.39M | -$53.2M | -$86.2M | -$72.1M | -$610M | -$226M | — |
| Operating margin | 9.4% | -6185.2% | -4764.3% | -10225.4% | — | — | — |
| Net income | $10.9M | -$52.7M | -$88.6M | -$78.8M | -$615M | -$221M | -$1.08B |
| Net margin | 19.0% | -6127.6% | -4897.8% | -11174.8% | — | — | — |
| EPS (diluted) | $0.63 | -$0.76 | -$0.67 | -$0.41 | -$0.99 | -$0.31 | -$1.44 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$35.1M | -$48.1M | -$72.6M | -$41.6M | -$76.8M | -$142M | -$323M |
| Capital expenditures | $157K | $421K | $306K | $624K | $128K | $139K | $657K |
| Free cash flow | -$35.3M | -$48.5M | -$72.9M | -$42.2M | -$76.9M | -$142M | -$324M |
| Dividends paid | $0.00 | $0.00 | — | — | — | — | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $63.8M | $66.4M | $71.8M | $349M | $71.4M | $105M | $225M |
| Total assets | $96.2M | $102M | $113M | $664M | $203M | $436M | $751M |
| Total liabilities | $17.4M | $23.0M | $30.1M | $538M | $125M | $46.8M | $92.3M |
| Shareholders' equity | $78.9M | $79.5M | $83.3M | $127M | $77.7M | $389M | $659M |
| Retained earnings | -$158M | -$211M | -$300M | -$378M | -$993M | -$1.21B | -$2.29B |
| Shares (wtd avg diluted) | 17.2M | 69.5M | 132M | 193M | 620M | 719M | 748M |
Every figure is extracted from Summit Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.